Acarix is in full swing with the launch of CADScor System, an acoustic and AI-based technology for the diagnosis of cardiovascular diseases. Recently, the step was taken to enter the US market, and now the company is carrying out a rights issue to keep up the pace of that investment. BioStock contacted Acarix's CEO Helen Ljungdahl Round to find out more about CADScor System, the launch, and the issue that the company is currently working on.
